Alterity Therapeutics Announces New Director Appointment and Securities Interests
Alterity Therapeutics has appointed David Stamler as a director, effective November 21, 2025, and disclosed his securities interests, including shares and options. This appointment may impact the company's governance and strategic direction, highlighting its commitment to strengthening leadership. Alterity Therapeutics focuses on developing therapies for neurodegenerative diseases.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Alterity Therapeutics ( (AU:ATH) ) has provided an announcement.
Alterity Therapeutics Limited has announced the appointment of David Stamler as a director, effective November 21, 2025. This appointment is accompanied by a detailed disclosure of Stamler’s interests in the company’s securities, which include a significant number of fully paid ordinary shares and various options. This move is likely to impact the company’s governance and could influence its strategic direction, reflecting the company’s ongoing commitment to strengthening its leadership team.
More about Alterity Therapeutics
Alterity Therapeutics Limited operates in the biotechnology industry, focusing on developing therapies for neurodegenerative diseases. The company is dedicated to creating innovative treatments to address unmet medical needs in this sector.
Average Trading Volume: 14,994,693
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$97.88M
Find detailed analytics on ATH stock on TipRanks’ Stock Analysis page.
